CIA Sample Clauses

CIA. As of the Effective Date, other than the CIA, AstraZeneca and its Affiliates are not a party to or bound by any other agreements or contracts with any Regulatory Authority, or bound by any orders, consent decrees, or other similar directives of any Regulatory Authority, that would be reasonably likely to have a material adverse effect on Impax’ ability to Commercialize the Existing Products in the Territory in accordance with Applicable Law; provided that nothing contained herein is intended or shall be construed to include any representation or warranty with respect to any requirement arising under Regulatory Approval or Applicable Law.
AutoNDA by SimpleDocs
CIA. The OIG negotiates corporate integrity agreements (CIAs) with health care providers and other entities as part of the settlement of Federal health care program investigations arising under a variety of civil false claims statutes.
CIA. Buyer shall give all Hired Active Employees credit for service with Seller in determining their respective entitlement to vacation days, sick days, personal days and other similar benefits to which Buyer’s employees are generally entitled.
CIA. Sanofi and certain Affiliates have entered into the Corporate Integrity Agreement, dated August 17th, 2015 with the Office of Inspector General of the Department of Health and Human Services (the “CIA”) to promote compliance with Federal healthcare requirements (as further described therein). Under the CIA, Provention may be deemed a “Third Party Personnel” (as specifically defined by the CIA). As such and in accordance with the CIA, Provention shall participate in CIA specific training obligations at Sanofi’s sole expense to the extent required by the CIA and notified by Sanofi to Provention in writing. Sanofi represents and warrants that, on or prior to the Effective Date, it has: (a) notified Provention in writing that Provention may be deemed “Third Party Personnel” under the CIA (and, thereafter, will renew such notification annually for the term of the CIA), (b) provided Provention with a copy of the CIA, (c) provided Provention with a summary of Sanofi’s obligations under the CIA, (d) provided Provention with a copy of Sanofi’s Code of Ethics (hxxxx://xxx.xxxxxxxxxxxx.xxxxxx/XX.html), and (e) provided Provention with a description of Sanofi’s Affiliates compliance program under the CIA. Provention hereby commits to make the above-mentioned Sanofi’s Code of Ethics and description of Sanofi’s compliance program under the CIA available to Provention members of the Product Personnel.
CIA. Vale do Rio Doce (CVRD) Mauritania.—Societe Nationale Industrielle completed a $25 million expansion of its Ponta et Miniere (SNIM) opened the M'Haoudat iron de Madeira port in Maranhao State, increasing mine in northeast Mauritania. buyer and seller. About 80% of domestic ore is produced by captive mines (mines producing for company smelters) and therefore does not reach the open market. The average f.o.b. mine value of usable ore shipped in 1994 was $27.44 per ton, slightly higher than that of 1994. This average value was based primarily on producers' statements and should approximate the average the shipping capacity from 35 to 50 Mmt/a of iron ore. The expansion enabled the port, which serves the Carajas Mine, to accommodate two large vessels at once. Mineracoes Brasileiras Reunidas S.A. (MBR) MBR, the country's second largest iron ore producer after CVRD, inaugurated the expansion of its Pico do Itabirita Mine. The
CIA. (2018). The World Factbook: Korea, South. Retrieved from xxxxx://xxx.xxx.xxx/library/publications/the-world-factbook/geos/ks.html
CIA. The World Factbook--Central Intelligence Agency: Bolivia. 2017. (xxxxx://xxx.xxx.xxx/library/publications/resources/the-world- factbook/geos/bl.html). (Accessed 11/14/2017).
AutoNDA by SimpleDocs

Related to CIA

  • KYC Following its request therefor, each Lender shall have received the documentation and other information that is required by regulatory authorities under applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)).

  • Applicable Law and Dispute Resolution 11.1 The execution, validity, performance and interpretation of this Agreement shall be governed by and construed in accordance with the laws of the PRC.

  • Quality Agreement Concurrently with execution of this Agreement, the Parties will enter into an agreement that details the quality assurance obligations of each Party with respect to the Manufacture and supply of Supplied Products under this Agreement (the “Quality Agreement”). Each Party shall perform its obligations under the Quality Agreement in accordance with the terms and conditions thereof. In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the provisions of the Quality Agreement shall govern.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.